LifeSignals receives CE Mark Approval for LifeSignals LX1550E Multiparameter Remote Monitoring Platform

LifeSignals Inc., today announced the CE (Conformité Européene) Mark for the LifeSignals LX1550E Multiparameter Remote Monitoring Platform – which can be used by clinicians for the continuous collection of physiological data of patients at home and in healthcare settings.

The single-use, wearable medical biosensor, records Electrocardiography (2-channel ECG), Heart Rate, Respiration rate, Skin Temperature and Body Posture data for up to five days. The encrypted physiological data can then be transmitted with high reliability from the LifeSignals Biosensor, via the Relay App to a secure cloud-based platform. Clinicians and Care Providers can access the cloud-based LifeSignals Remote Monitoring Dashboard to view patient physiological data and manage vital sign alert settings.

The LifeSignals Remote Monitoring Platform is designed to enable healthtech companies to rapidly enhance their product and service portfolios to provide vital sign monitoring to the widest possible patient base, from any location. The interoperable platform can be tailored with ready-to-deploy software development kit APIs and is suitable for large scale implementation.

“COVID-19 has accelerated the adoption of remote patient monitoring globally,” says Steve Jones, Business Development Director, Europe. “This regulatory approval for our Multiparameter Platform is a significant breakthrough and will enable our Partners to bring to market affordable and scalable remote monitoring products and solutions”.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”